Liver International Special Issue: Treatment of HCV with direct-acting antiviral agents: 100% cure?

Liver International

Full text articles are open access, see index of review articles below. 

Special Issue:
Proceedings of the 11th Paris Hepatology Conference. International Conference on the Management of Liver Diseases  

Proceedings of the 11th Paris Hepatology Conference. International Conference on the Management of Liver Diseases: 15–16 January 2018, Paris, France. 


Review Article
Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?
Tarik Asselah, Patrick Marcellin, Raymond F. Schinazi

Full Text
View Online
Download PDF

Abstract
Around 71 million people are chronically infected with HCV worldwide. HCV antiviral drug development has been remarkable. The availability of pangenotypic direct-acting antivirals with excellent efficacy and good tolerability profiles offer a unique opportunity to achieve HCV elimination worldwide. IFN-free DAA combinations can now cure HCV in more than 95% of patients with HCV infection after 8-12 weeks of treatment. Programmes to eliminate HCV must include increased screening (risk-based and universal), linkage to care, as well as increased access to treatment worldwide. In this paper, we will review the available data on recently approved direct-acting antiviral agents, with sustained virological response that reaches almost 100%.

Continue to full text article

Index
REVIEW ARTICLES
Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening (pages 2–6)

http://hepatitiscnewdrugs.blogspot.com/2018/02/liver-international-special-issue.html

Leave a Reply

Your email address will not be published. Required fields are marked *